格隆汇2月27日丨泽璟制药(688266.SH)公布2025年度业绩快报，公司2025年度实现营业收入8.13亿元， 同比上年增长52.50%；归属于上市公司股东的净利润为-1.61亿元，归属于上市公司股东的扣除非经常 性损益的净利润为-2.12亿元，亏损同比上年有所增加；加权平均净资产收益率-13.76%，亏损同比增加 4.34个百分点。 报告期内，吉卡昔替尼片获批上市销售，公司努力开拓市场，提升药品的市场覆盖率；重组人凝血酶正 式纳入国家医保目录，公司与独家市场推广合作伙伴合作顺利，药品准入医院数量和销量快速提升；同 时，公司持续推进新药研发，因新药研发项目所处具体研发阶段不同，研发费用同比增加。 ...

格隆汇2月27日丨泽璟制药(688266.SH)公布2025年度业绩快报，公司2025年度实现营业收入8.13亿元， 同比上年增长52.50%；归属于上市公司股东的净利润为-1.61亿元，归属于上市公司股东的扣除非经常 性损益的净利润为-2.12亿元，亏损同比上年有所增加；加权平均净资产收益率-13.76%，亏损同比增加 4.34个百分点。 报告期内，吉卡昔替尼片获批上市销售，公司努力开拓市场，提升药品的市场覆盖率；重组人凝血酶正 式纳入国家医保目录，公司与独家市场推广合作伙伴合作顺利，药品准入医院数量和销量快速提升；同 时，公司持续推进新药研发，因新药研发项目所处具体研发阶段不同，研发费用同比增加。 ...

泽璟制药晚间公告，2025年度实现营业收入8.13亿元，同比增长52.50%；归属于上市公司股东的净亏损 1.61亿元，上年同期净亏损1.38亿元。2025年末，公司总资产29.71亿元，归属于母公司的所有者权益 10.83亿元。报告期内，吉卡昔替尼片获批上市销售，公司努力开拓市场，提升药品的市场覆盖率；重 组人凝血酶正式纳入国家医保目录，公司与独家市场推广合作伙伴合作顺利，药品准入医院数量和销量 快速提升；同时，公司持续推进新药研发，因新药研发项目所处具体研发阶段不同，研发费用同比增 加。 ...

Core Viewpoint - Zai Lab (688266) has entered a strategic collaboration with AbbVie for the global development and commercialization of ZG006, receiving an upfront payment of $100 million and potential milestone payments up to $1.075 billion, along with tiered royalties [1][4]. Group 1: Company Developments - Zai Lab's stock price increased by 3.27% this week, closing at 94.42 CNY, with a market capitalization of 24.994 billion CNY, ranking 16th in the chemical pharmaceutical sector [1]. - ZG006 has shown significant efficacy in treating small cell lung cancer, with an overall response rate (ORR) of 60.0% in the recommended dose group and a confirmed ORR of 53.3% [1][4]. - ZG005 has demonstrated an ORR of 40.9% in second-line and above cervical cancer patients, with a median progression-free survival (mPFS) exceeding 11 months [2][4]. - The injection of human thyroid-stimulating hormone beta (Zesuneng) was approved on January 8 for use in post-operative follow-up of differentiated thyroid cancer, with marketing efforts led by Merck in China [2][4]. - The drug Jikaxitini tablets were included in the national medical insurance directory effective January 1, 2026, and are recommended as a first-line treatment for anemia in myelofibrosis [2][4]. Group 2: Financial Performance - The company expects its revenue for 2025 to be between 796.49 million CNY and 828.99 million CNY, representing a year-on-year growth of 49.45% to 55.55%, primarily driven by increased sales of recombinant thrombin and the launch of Jikaxitini tablets [3][4]. - Despite revenue growth, the company anticipates a net loss due to increased sales and research expenses [3]. Group 3: Shareholder Actions - The chairman and major shareholder, Zelin Sheng, plans to reduce his holdings by up to 273,907 shares (0.1035%), while Ningbo Zeao intends to reduce its holdings by up to 2,475,090 shares (0.9350%) between March 17 and June 16, 2026 [3][4].

业绩经营情况 公司预计2026年营收为7.96亿至8.29亿元，同比增长49.45%至55.55%，主要受益于重组人凝血酶医保放 量及吉卡西替尼商业化推进。 泽璟制药与艾伯维就ZG006药物达成全球开发及商业化协议，艾伯维获得大中华区以外独家权利；泽璟 已收到1亿美元首付款，并可能获得最高6000万美元近期里程碑付款及10.75亿美元远期里程碑付款。 ZG006针对小细胞肺癌和神经内分泌癌的临床试验数据显示，在II期剂量优化试验中，10mg组确认客观 缓解率（ORR）达53.3%，中位无进展生存期（mPFS）为7.03个月。 产品研发进展 除ZG006外，注射用ZG005在宫颈癌II期临床试验中确认ORR为40.9%，疾病控制率（DCR）68.2%；公 司多款候选药物如ZGGS18、ZGGS34等已进入中美I期临床阶段。 经济观察网 根据截至2026年2月14日的公开信息，泽璟制药-U（688266.SH）近期有以下事件值得关 注： 高管减持 公司公告称，股东ZELIN SHENG（盛泽林）拟减持不超过273,907股（占总股本0.1035%），股东宁波 泽奥拟减持不超过2,475,090股（占总股本0.93 ...

2026年2月13日，泽璟制药披露接待调研公告，公司于2月2日至2月10日接待淡水泉、农银汇理、安信基 金、华安基金、建信资产、平安基金等28家机构调研。 调研情况显示，泽璟制药与艾伯维就ZG006达成全球开发及商业化战略合作与许可选择权协议，艾伯维 获大中华区以外地区独家权利，泽璟保留区内权利；泽璟已收到1亿美元首付款，还可获最高6000万美 元近期里程碑及许可选择付款，若选择权行使另有最高10．75亿美元里程碑付款和高个位数到中双位数 阶梯特许权使用费。ZG006正推进单药及联合用药治疗小细胞肺癌、神经内分泌癌等临床试验，包括关 键及III期试验；在晚期小细胞肺癌三线及以上II期剂量优化试验中，10mg每两周一次组确认ORR为53． 3％、mPFS达7．03个月，6个月及12个月OS率分别为83．2％及69．1％；治疗神经内分泌癌推荐剂量 组全人群确认ORR38．5％，DLL3阳性患者达66．7％。 注射用ZG005正推进单药及联合用药治疗肝癌、神经内分泌癌、宫颈癌等试验；二线及以上宫颈癌 20mg／kg Q3W方案确认ORR40．9％、DCR68．2％、mPFS超11个月，联合方案一线宫颈癌及早期肝 癌 ...

Core Viewpoint - Zai Jian Pharmaceutical (688266.SH) expects significant revenue growth in 2025, with projected revenues between 796.49 million and 828.99 million yuan, representing a year-on-year increase of 49.45% to 55.55% [1] Financial Performance - The company anticipates a net loss attributable to shareholders of the parent company ranging from 191.39 million to 139.60 million yuan for 2025, an increase in losses by 1.76 million to 53.56 million yuan compared to the previous year [1] - The expected net loss after deducting non-recurring gains and losses is projected to be between 237.87 million and 172.53 million yuan, reflecting an increase in losses by 1.37 million to 66.71 million yuan year-on-year [1] Revenue Drivers - The significant revenue growth is primarily attributed to an increase in drug sales, particularly due to the inclusion of recombinant human thrombin in the national medical insurance drug list, which has led to a noticeable increase in sales [1] - The approval and commercialization of Jikaxitini tablets during the reporting period have also contributed to the revenue growth [1] Expense Overview - Despite the revenue increase, the company continues to report negative net profits, with the anticipated losses attributed mainly to rising sales and research and development expenses [1]

Investment Rating - The report initiates coverage on Zai Lab with a "Buy" rating and a target price of RMB 166.16 [1][6] Core Insights - Zai Lab is a leading player in the TCE (T cell engager) field, with its flagship product ZG006 (DLL3/DLL3/CD3) expected to achieve a domestic peak sales of over RMB 4 billion and an overseas peak of nearly USD 6 billion [2][19] - The company has four innovative drugs already approved for sale in China, providing a sustainable cash flow to support early-stage R&D pipelines [1][15] - Zai Lab has partnered with AbbVie to expand ZG006 into international markets, which is anticipated to accelerate clinical progress and enhance market penetration [2][19] Summary by Sections Investment Rating - The report assigns a "Buy" rating to Zai Lab with a target price of RMB 166.16 [1][6] Market Potential - ZG006 is projected to have a domestic peak sales of over RMB 4 billion and an overseas peak of nearly USD 6 billion, driven by the high unmet medical need in small cell lung cancer (SCLC) [2][19] - The report highlights the potential for ZG006 to achieve a significant market share in the first-line SCLC treatment, with expectations of a 30% peak market share due to AbbVie's commercialization capabilities [5][19] Product Pipeline - Zai Lab has a robust pipeline with multiple innovative drugs, including ZG005 (PD-1/TIGIT) and ZGGS34 (MUC17/CD3/CD28), which are in various stages of clinical trials [4][22] - The company has successfully commercialized four innovative drugs, including Donafenib, which generated approximately RMB 530 million in sales in 2024 [3][15] Financial Projections - The report forecasts Zai Lab's revenue to grow from RMB 843 million in 2025 to RMB 2.22 billion in 2027, with a projected net profit of RMB 5.46 million in 2025 [6][10] - The DCF valuation method estimates a target market capitalization of RMB 43.98 billion, corresponding to the target price of RMB 166.16 [6][10]

Core Viewpoint - Zai Jing Pharmaceutical, the first innovative drug company to list on the STAR Market under the "Fifth Set of Standards," has struggled to achieve profitability since its IPO in 2020, despite launching several products and transitioning from a clinical biotech firm to a commercial pharmaceutical company [4][6][9]. Financial Performance - Since its listing, Zai Jing Pharmaceutical has reported continuous losses, with a net loss of 1.5 billion RMB in 2024 and a net loss of 1.38 billion RMB [6][10]. - As of the end of Q3 2025, the company reported revenues of 5.93 billion RMB, surpassing the total revenue for 2024 [10][11]. - The company's debt ratio exceeded 60% by Q3 2025, with total liabilities reaching 18.64 billion RMB, primarily driven by short-term debts [17][18]. Product Development and Sales - Zai Jing Pharmaceutical's product portfolio includes multiple drugs, with its main revenue source being Donafenib, which has been approved for use in over 2,200 hospitals [20][21]. - The company has launched several products, including Donafenib, Recombinant Human Thrombin, and JAK inhibitor Gika Xitini, with the latter expected to enter the national medical insurance directory in January 2026 [8][21]. - Despite revenue growth, the company faces high sales and distribution expenses, which reached 3.32 billion RMB in the first three quarters of 2025, indicating a sales expense ratio of over 56% [9][21]. Strategic Moves - Zai Jing Pharmaceutical is pursuing a dual listing on the Hong Kong Stock Exchange to raise funds for international expansion and brand establishment [11][12]. - The company recently announced a licensing deal with AbbVie for its drug ZG006, which could provide up to 1 billion USD in milestone payments, marking its first overseas licensing agreement [16][24]. - The cancellation of its U.S. subsidiary, Gensun Biopharma, was aimed at optimizing resource allocation and enhancing R&D efficiency, although it raised questions about the rationale behind the acquisition of a loss-making asset [12][15]. Market Sentiment - The stock price of Zai Jing Pharmaceutical saw a nearly 50% increase in the first half of 2025, but market sentiment has shifted, with concerns about the company's ability to achieve profitability and manage high sales expenses [22][23]. - As of January 8, 2026, the stock price was reported at 97.25 RMB per share, reflecting a decline, indicating market skepticism regarding the company's future performance [23][24].

Core Viewpoint - Zai Jing Pharmaceutical has announced a strategic collaboration and licensing agreement with AbbVie for the global development and commercialization of ZG006, potentially generating up to $1.235 billion in revenue for the company [1][5]. Group 1: Financial Performance - Zai Jing Pharmaceutical reported a record revenue of 593 million yuan for the first three quarters of 2025, continuing a trend of rapid revenue growth since 2021 [1]. - Despite the revenue growth, the company has not achieved profitability since its IPO in 2020, accumulating a total net loss of 1.738 billion yuan by 2025 [8][9]. - The company has seen a decrease in R&D investment from 509 million yuan in 2021 to 388 million yuan in 2024, with a slight increase in 2025 [9]. Group 2: Strategic Developments - The collaboration with AbbVie grants the latter exclusive rights to develop and commercialize ZG006 outside Greater China, while Zai Jing retains rights within the region [4][5]. - ZG006 is a novel trispecific T-cell engager targeting DLL3, currently in late-stage clinical development for small cell lung cancer and other DLL3-expressing malignancies [4]. - The agreement includes an upfront payment of $100 million and potential milestone payments totaling up to $1.235 billion, significantly enhancing the company's financial outlook [5]. Group 3: Market Position and Future Plans - Zai Jing Pharmaceutical is pursuing an IPO on the Hong Kong Stock Exchange to support its internationalization strategy and enhance brand recognition [2][10]. - The company aims to leverage the collaboration with AbbVie to expand ZG006 into multiple indications and improve its global market presence [5]. - The strategic focus includes addressing unmet medical needs in oncology and blood diseases, with a pipeline covering 29 projects [7].